Clover to Add Dynavax's Adjuvant to its COVID-19 Vaccine Candidate

Chengdu's Clover Bio will collaborate with Dynavax to conduct pre-clinical tests of Clover's COVID-19 vaccine candidate combined with Dynavax's vaccine adjuvant, CpG 1018. Based on the genomic sequence of the SARS-CoV-2 virus, Clover applied its patented Trimer-Tag© technology to produce a COVID-19 S-Trimer subunit vaccine candidate that resembles the native trimeric viral spike to prevent entry of the virus into cells. More details.... Stock Symbol: (NSDQ: DVAX) Share this with colleagues: // //